Who Owns Eikon Therapeutics Stock?
NASDAQ: EIKNHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
Ownership breakdown
- Held by institutions
- 78.67%
- Held by insiders
- 17.37%
- Institutional holders
- 132
- Institutions 78.7%
- Insiders 17.4%
- Public and other 4.0%
Who owns Eikon Therapeutics stock?
Institutional investors own about 78.7% of Eikon Therapeutics's shares, spread across 132 institutions that file 13F reports. That level of institutional ownership is high, typical of large, widely followed companies. Insiders, including executives, directors and large founding shareholders, hold 17.37% of EIKN.
The largest institutional holders are FMR, LLC (10.19%), Blackrock Inc. (8.99%) and Foresite Capital Management IV, LLC (3.59%). Together, the top 10 institutions control 39.3% of shares outstanding. In their latest filings, 6 of the top 10 institutions increased their EIKN positions and 0 reduced them.
Summary generated from market data by MetaCap's automated system. Methodology
Top institutional holders of EIKN
| Institution | Shares | % Held | Change |
|---|---|---|---|
| FMR, LLC | 5.52M | 10.19% | +10.5% |
| Blackrock Inc. | 4.87M | 8.99% | +13.7% |
| Foresite Capital Management IV, LLC | 1.94M | 3.59% | 0.0% |
| Merck & Co., Inc. | 1.67M | 3.08% | 0.0% |
| T. Rowe Price Investment Management, Inc. | 1.64M | 3.02% | +2.6% |
| Foresite Capital Management V, LLC | 1.32M | 2.43% | 0.0% |
| Capital World Investors | 1.18M | 2.17% | 0.0% |
| Price (T.Rowe) Associates Inc | 1.11M | 2.05% | +10.5% |
| Alliancebernstein L.P. | 1.05M | 1.94% | +63.9% |
| Vanguard Capital Management LLC | 1.02M | 1.87% | +10.1% |
% held is the share of total shares outstanding. Change is the percentage change in the position since the holder's previous 13F filing.
Top mutual fund and ETF holders of EIKN
| Fund | Shares | % Held |
|---|---|---|
| Fidelity Contrafund | 1.27M | 2.35% |
| Fidelity Select Portfolios-Select Biotechnology Portfolio | 1.18M | 2.17% |
| SmallCap World Fund Inc | 1.14M | 2.11% |
| T. Rowe Price Small-Cap Value Fund, Inc. | 926.05K | 1.71% |
| iShares Trust-iShares Russell 2000 ETF | 809.97K | 1.49% |
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 794.02K | 1.47% |
| BlackRock Funds-BlackRock Health Sciences Opportunities Portfolio | 722.39K | 1.33% |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 660.12K | 1.22% |
| TR PRICE-Price (T.Rowe) U.S. Small-Cap Value Equity Trust | 606.52K | 1.12% |
| AB CAP FUND, INC.-AB Small Cap Growth Portfolio | 434.43K | 0.80% |
Frequently asked questions
Who is the largest shareholder of Eikon Therapeutics?
FMR, LLC is the largest institutional shareholder of EIKN, owning 10.19% of shares outstanding (5.52M shares) as of its latest 13F filing.
What percentage of Eikon Therapeutics is owned by institutions?
Institutions own about 78.7% of EIKN shares and 95.2% of the public float.
How much of Eikon Therapeutics do insiders own?
Insiders, such as officers and directors, own about 17.37% of EIKN shares outstanding.
Where does institutional ownership data come from?
Investment managers with more than $100 million in US equities must file Form 13F with the SEC within 45 days of each quarter-end. Holdings are therefore up to about 4.5 months old when published.